Organogenesis Holdings Inc. Stock Nasdaq
Equities
AHPAU
KYG0726L1095
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% | +1.51% | +0.58% |
Feb. 29 | Transcript : Organogenesis Holdings Inc., Q4 2023 Earnings Call, Feb 29, 2024 | |
Feb. 29 | Organogenesis Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | 455M | Sales 2025 * | 490M | Capitalization | 302M |
---|---|---|---|---|---|
Net income 2024 * | -2M | Net income 2025 * | 8M | EV / Sales 2024 * | 0.63 x |
Net cash position 2024 * | 15.31M | Net cash position 2025 * | 14.68M | EV / Sales 2025 * | 0.58 x |
P/E ratio 2024 * |
-171
x | P/E ratio 2025 * |
24.1
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 66.31% |
Latest transcript on Organogenesis Holdings Inc.
Managers | Title | Age | Since |
---|---|---|---|
Gary Gillheeney
CEO | Chief Executive Officer | 69 | 13-12-31 |
David Francisco
DFI | Director of Finance/CFO | 59 | 21-02-15 |
Patrick Bilbo
COO | Chief Operating Officer | 63 | 98-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Glenn Nussdorf
BRD | Director/Board Member | 70 | 02-12-31 |
Alan Ades
BRD | Director/Board Member | 86 | 02-12-31 |
Michael Driscoll
BRD | Director/Board Member | 63 | 22-02-14 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.59B | |
+8.57% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.92% | 24.81B | |
-25.13% | 18.17B | |
+29.17% | 12.05B | |
-3.12% | 11.7B | |
+6.35% | 11.1B |
- Stock Market
- Equities
- ORGO Stock
- AHPAU Stock